GlassScriptPhysician profile
Alexandra Wong
NPI 1639673783
$4,271.36
in general payments reported to CMS, 2019-2025
26 companies · $48.93 in 2025
The $48.93 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $504 · 2022: $1,063 · 2023: $1,692 · 2024: $962 · 2025: $48.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.98 |
| Education | $103.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $925.26 | 2021-2024 | Pomalyst, Reblozyl |
| Genzyme Corporation | $553.05 | 2021-2024 | |
| Abbvie INC. | $398.89 | 2023-2024 | |
| Incyte Corporation | $364.21 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $316.06 | 2021-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $204.32 | 2022-2024 | Keytruda, Prevymis |
| Emd Serono, INC. | $170.27 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $160.48 | 2022-2023 | Libtayo |
| Seagen INC. | $154.17 | 2022-2023 | Tukysa |
| Blueprint Medicines Corporation | $146.26 | 2024 | Ayvakit |
| Jazz Pharmaceuticals INC. | $138.75 | 2023 | Rylaze |
| Astrazeneca Pharmaceuticals LP | $117.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.38 | 2023 | Pomalyst |
| Ipsen Biopharmaceuticals, INC | $97.79 | 2022-2024 | Onivyde, Somatuline Depot |
| Servier Pharmaceuticals LLC | $71.19 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $63.08 | 2022-2025 | Qinlock, Tgct |
| Puma Biotechnology, INC. | $59.83 | 2023-2024 | Nerlynx |
| Novartis Pharmaceuticals Corporation | $55.18 | 2024 | |
| Astellas Pharma US INC | $26.67 | 2025 | Xospata |
| Aveo Pharmaceuticals, INC. | $26.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.04 | 2022 | |
| Janssen Biotech, INC. | $25.46 | 2024 | Tecvayli |
| Janssen Pharmaceuticals, INC | $21.70 | 2024 | |
| Recordati_rare_diseases_inc. | $16.81 | 2024 | Sylvant |
| Karyopharm Therapeutics INC. | $16.64 | 2021 | |
| Gilead Sciences, INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.